Motoyama Y, Seki J, Katoh Y, Nishio M, Yoshida K
New Drug Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan.
Atherosclerosis. 1994 Aug;108(2):159-65. doi: 10.1016/0021-9150(94)90110-4.
The effect of TFC-612, methyl-6-(1R,2S,3R)-hydroxy-2--3- hydroxy-5-methyl-1-nonenyl]-5-oxocyclopentyl)thio] hexanoate, on intimal thickening of carotid artery 14 days after endothelium denudation with a balloon catheter was examined in rats. This compound significantly suppressed the neointimal area and the ratio of intimal and medial layer by 41.1% and 31.4%, respectively, at 3.2 micrograms/rat/h s.c. infusion. At this dose, this compound did not inhibit platelet aggregation induced by either collagen or ADP. It did not inhibit bromodeoxyuridine incorporation into medial smooth muscle cells at 3 days after injury. In in vitro experiments, TFC-612 did not inhibit the [3H]thymidine uptake into cultured smooth muscle cells, but it showed significant inhibition of smooth muscle cell migration induced by platelet-derived growth factor (PDGF) at more than 10(-9) M. This compound increased cyclic AMP levels dose dependently in cultured smooth muscle cells at more than 10(-8) M. These results suggest that TFC-612 inhibits intimal thickening by inhibition of smooth muscle cell migration from media to intima through cyclic AMP elevation.
研究了TFC-612(6-(1R,2S,3R)-羟基-2--3-羟基-5-甲基-1-壬烯基]-5-氧代环戊基)硫代]己酸甲酯对大鼠经球囊导管剥脱内皮14天后颈动脉内膜增厚的影响。以3.2微克/大鼠/小时的皮下输注剂量,该化合物分别使新生内膜面积和内膜与中膜层比例显著降低了41.1%和31.4%。在此剂量下,该化合物不抑制胶原蛋白或ADP诱导的血小板聚集。它在损伤后3天不抑制溴脱氧尿苷掺入中膜平滑肌细胞。在体外实验中,TFC-612不抑制[3H]胸腺嘧啶核苷摄取到培养的平滑肌细胞中,但在浓度高于10(-9)M时,它对血小板衍生生长因子(PDGF)诱导的平滑肌细胞迁移有显著抑制作用。该化合物在浓度高于10(-8)M时,能剂量依赖性地增加培养的平滑肌细胞中环磷酸腺苷(cAMP)水平。这些结果表明,TFC-612通过升高环磷酸腺苷(cAMP)抑制平滑肌细胞从内膜向中膜迁移,从而抑制内膜增厚。